[1] It allows for precise control over the composition and dosage of drugs, enabling the production of personalized medicine tailored to an individual's specific needs, such as age, weight, and medical condition.
[8] This area which is a part of biomaterials engineering, aims at products such as adhesive patches for wound healing, hydrogel, and non-hydrogel implants, rather than tablets or capsules.
The binder jet approach begins by spreading a fine layer of powder onto the platform using a roller.
[9] Subsequently, a removable printhead sprays droplets, selectively binding the powder to create the desired structure.
[11] Fused deposition modeling technology[12] was made available to the public domain in 2009, and is currently a commonly used approach to 3D drug printing.
The process is initiated by introducing active pharmaceutical ingredients (API) and various excipients into separate feeding devices.
These materials are then subjected to heat and intense shearing within the hot melt extrusion system, resulting in a uniform molten state.
Precise control of pressure and temperature results in the creation of 3D-printed preparations that closely replicate the desired structure.
Moreover, basically no post-processing is needed due to the dry printing conditions and lack of supporting structures.
In SSE, an extrusion head follows a predefined path, depositing semisolid material to create each layer, and gradually stacking them to form the final product.
[18] The printing process can be configured to work either from the top to the bottom or vice versa, depending on the printer's setup.